BioSpace News Archive

RhoVac AB, a Swedish cancer immunotherapy company, regrets to announce on May 29th, 2022, that its phase IIb study in prostate cancer, BRaVac, in spite of the previous positive results related to the compound, failed to demonstrate RV001 superiority over placebo in preventing progression in patients with biochemical recurrence after curative intent therapy.

InxMed Co., Ltd is pleased to announce that the clinical data from an open-label phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase, in combination with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent ovarian cancer, will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology from June 3, 2022 to June 7, 2022.

Taiwan-based United BioPharma has announced the approval of a Phase 2 clinical trial with novel anti-IgE monoclonal antibody UB-221 by the Taiwan Food and Drug Administration.